Continuous Positive Airway Pressure for Acute Pulmonary Edema

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

208 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesise that CPAP + pharmaceutical treatment, compared to pharmaceutical treatment alone, improves the respiratory and hemodynamic status of the patients before H2 after the inclusion time and decreases the rate of death and tracheal intubation during the first 48 hours.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Out-of-Hospital CPAP for Severe Cardiogenic Pulmonary Edema

NCT00390442

Cardiogenic Pulmonary Edema

COMPLETED PHASE3

OUT-OF-HOSPITAL CPAP STUDY

NCT00439075

Acute Cardiogenic Pulmonary Edema

COMPLETED PHASE4

CPAP Versus Bilevel Pressure Support Ventilation in Cardiogenic Pulmonary Edema

NCT00213681

Severe Acute Cardiogenic Pulmonary Edema

COMPLETED PHASE3

Helmet CPAP vs Facemask CPAP in ACPE (hCPAP vs fCPAP)

NCT04014088

Acute Cardiogenic Pulmonary Edema

COMPLETED NA

Non Invasive Mechanical Ventilation in Acute Cardiogenic Pulmonary Edema

NCT00912158

Acute Cardiogenic Pulmonary Edema

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients are included at home after informed consent by the emergency medical team and transported during the following 2 hours to a cardiac intensive care unit were the treatment is purchased as well. Randomization process has been done previously with envelopes ; group A : pharmaceutical treatment alone , B pharmaceutical plus CPAP. Medical treatment includes furosemide and nitroglycerin (continuous perfusion and bolus), inotropes if needed, and all other specific treatment required (ex : anti antiarrhythmic drugs). Doses are free, adapted to the clinical response for respiratory and hemodynamic distress. CPAP is a passive high flow venturi system device alimented by a hyperbaric oxygen. FiO2 can be controlled and adapted to the pulsed oxygen saturation. PEP must be initially celled at least at 7.5 cmH2O and increased to 10 if well tolerated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Edema Dyspnea Paroxysmal Congestive Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Usual care of pulmonary acute oedema

Group Type ACTIVE_COMPARATOR

usual care of acute pulmonary oedema

Intervention Type PROCEDURE

Usual treatment of acute pulmonary oedema including :

Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.

Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.

As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min.

B

CPAP + usual care of pulmonary acute oedema

Group Type EXPERIMENTAL

Continuous Positive Airway Pressure (CPAP)

Intervention Type PROCEDURE

Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:

stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Continuous Positive Airway Pressure (CPAP)

Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:

stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status.

Intervention Type PROCEDURE

usual care of acute pulmonary oedema

Usual treatment of acute pulmonary oedema including :

Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.

Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.

As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \> 18
* acute respiratory insufficiency with hypoxia in air
* KILLIP score from 2 to 4
* absence of known ST elevation acute coronary syndrome
* accepted inform consent.